Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.215 USD | +1.32% | -5.30% | -29.97% |
Financials (USD)
Sales 2024 * | 395M | Sales 2025 * | 484M | Capitalization | 858M |
---|---|---|---|---|---|
Net income 2024 * | -128M | Net income 2025 * | -65M | EV / Sales 2024 * | 2.76 x |
Net Debt 2024 * | 234M | Net Debt 2025 * | 259M | EV / Sales 2025 * | 2.3 x |
P/E ratio 2024 * |
-6.6
x | P/E ratio 2025 * |
-12
x | Employees | 536 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
Latest transcript on BioCryst Pharmaceuticals, Inc.
1 day | -1.19% | ||
1 week | -7.56% | ||
Current month | -18.11% | ||
1 month | -15.27% | ||
3 months | -23.67% | ||
6 months | -23.95% | ||
Current year | -30.55% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 20-04-01 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 20-02-26 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Director/Board Member | 60 | 21-07-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.23% | 0 M€ | 0.00% | - | |
0.20% | 0 M€ | 0.00% | - | |
0.18% | 1,026 M€ | +6.15% | - | |
0.13% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 4.2 | +0.96% | 122 780 |
24-04-25 | 4.16 | -1.19% | 2,735,562 |
24-04-24 | 4.21 | -3.88% | 4,409,981 |
24-04-23 | 4.38 | -0.68% | 4,236,664 |
24-04-22 | 4.41 | -0.45% | 2,557,483 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.55% | 858M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- BCRX Stock